Japanese Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

JJCO Paper of the Year and Highly Commended Paper
We are pleased to announce that among the 108 original papers published in 2019, the Editorial Board selected the following paper for the award. The Editorial Board members and Oxford University Press congratulate the authors for their excellent paper and hope that they will continue to submit their finest work to theJapanese Journal of Clinical Oncology (JJCO). Unfortunately, there was no award ceremony this year as the 34th JJCO Editorial Meeting, scheduled to take place in October, was cancelled due to current coronavirus pandemic. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 16, 2020 Category: Cancer & Oncology Source Type: research

Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data
ConclusionThis retrospective study of real-world data indicated that metastatic renal cell carcinoma outcomes improved with successive systemic therapy paradigms. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 15, 2020 Category: Cancer & Oncology Source Type: research

Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study
ConclusionsAbiraterone acetate plus prednisolone demonstrated a high prostate-specific antigen response rate of 55.1%, suggesting tumor growth still depends on androgen synthesis in patients with early metastatic castration-resistant prostate cancer. However, prostate-specific antigen –progression-free survival was shorter than that reported in previous studies. Considering the benefit–risk profile, abiraterone acetate plus prednisolone would be a beneficial treatment option for patients with chemotherapy-naive metastatic prostate cancer who show early castration resistance. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 15, 2020 Category: Cancer & Oncology Source Type: research

Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment
ConclusionsThe immunohistochemistry-based molecular subtypes could predict the patient ’s prognosis and clinically different chemotherapeutic survival outcomes in patients with T1 stage bladder cancer after bladder-preserving treatment. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 15, 2020 Category: Cancer & Oncology Source Type: research

Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
AbstractOver the past 10  years, immunotherapy with immune checkpoint inhibitors has revolutionized the management of various cancers. However, immunotherapy in breast cancer has not been successful. Breast cancer has long been recognized as an immunologically ‘cold’ tumor, although a higher frequency of tumor-infiltra ting lymphocytes present in certain subtypes and an association between tumor-infiltrating lymphocytes and favorable prognosis have been reported. In March 2019, the combination of atezolizumab and nanoparticle albumin-bound paclitaxel was granted accelerated approval in the United States for the tr eat...
Source: Japanese Journal of Clinical Oncology - December 15, 2020 Category: Cancer & Oncology Source Type: research

Expression and prognostic significance of NKD2 in ovarian cancer
ConclusionNKD2 is a novel prognostic marker and could suppress tumor progression in ovarian cancer. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 15, 2020 Category: Cancer & Oncology Source Type: research

Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group
AbstractThe standard therapy for all localized soft tissue sarcomas is surgical resection of the tumor. For patients with soft tissue sarcomas who are at high risk for recurrence and/or metastasis, perioperative chemotherapy is a potential treatment option. Adriamycin plus ifosfamide is currently the most promising chemotherapy regimen for localized soft tissue sarcomas. Randomized controlled trials and meta-analyses of adjuvant postoperative chemotherapy for soft tissue sarcomas have suggested that adjuvant chemotherapy may provide an advantage, however small, compared with surgery alone. On the other hand, recent randomi...
Source: Japanese Journal of Clinical Oncology - December 14, 2020 Category: Cancer & Oncology Source Type: research

Validity of measuring psoas muscle mass index for assessing sarcopenia in patients with gynecological cancer
ConclusionsAlthough relevance between skeletal muscle mass index and psoas muscle mass index was confirmed, intensity of relevance between them was weak. Psoas muscle mass index measurement should be subordinated to skeletal muscle mass index measurement for detection of low skeletal muscle mass. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 12, 2020 Category: Cancer & Oncology Source Type: research

Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event
ConclusionsTo avoid unnecessary steroid administration, colonoscopic evaluation is essential in patients receiving treatment with immune checkpoint inhibitors who present with diarrhea as an immune-related adverse event. In addition, the endoscopic findings could be useful to predict the response to steroid treatment. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 9, 2020 Category: Cancer & Oncology Source Type: research

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck
AbstractIn order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current s...
Source: Japanese Journal of Clinical Oncology - December 9, 2020 Category: Cancer & Oncology Source Type: research

Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan
ConclusionsThe safety and efficacy profiles in this postmarketing observational study were consistent with prior data and registration clinical trials. No new safety signals were observed while treating patients with metastatic soft tissue sarcoma with pazopanib. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 5, 2020 Category: Cancer & Oncology Source Type: research

Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer
ConclusionsPreoperative docetaxel, cisplatin and S-1 therapy was feasible in terms of chemotherapy-related toxicities and surgical morbidity, but the effect did not achieve the expected value. The association between the pathological response rate and survival will be evaluated in the final analysis of this clinical trial. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 3, 2020 Category: Cancer & Oncology Source Type: research

Does complete-staging lymphadenectomy improve survival outcomes in stage I endometrioid epithelial ovarian carcinoma? A multi-institutional retrospective study with propensity score-weighted analysis
ConclusionsComplete-staging lymphadenectomy was not a significant prognostic factor in patients with Stage I endometrioid epithelial ovarian carcinoma, where we still need to explore appropriate candidate for the procedure. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - December 1, 2020 Category: Cancer & Oncology Source Type: research

High-resolution 18F-FDG PET/MR offers better treatment evaluation than PET/CT or MRI in CNS lymphoma
A 27-year-old woman presented with right-sided mouth droop, dizziness and impaired memory. She was sent for a brain 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography –computed tomography (PET/CT) and positron emission tomography–magnetic resonance imaging (PET/MRI). Findings from the PET/CT showed an iso- to mild hyper-attenuated lesion, with avid-FDG uptake (SUVmax 24.7), in the cerebral parenchyma involving the left basal ganglia, frontal lobe, temporal lo be, insula, thalamus, cerebral peduncle, brain stem, genu of the corpus callosum and right basal ganglia. Findings from the PET/MR additionally showed ...
Source: Japanese Journal of Clinical Oncology - November 27, 2020 Category: Cancer & Oncology Source Type: research

Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population
ConclusionsThe prevalence of deficient mismatch repair prostate cancer in the Japanese hospital-based prostatectomized population was extremely low. To improve screening efficacy for deficient mismatch repair prostate cancer, screening candidates can be limited to patients with locally advanced, node-positive and/or Gleason score of 8 or greater prostate cancer. Universal tumour screening for Lynch syndrome seems ineffective in patients with prostate cancer. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - November 27, 2020 Category: Cancer & Oncology Source Type: research